Request a FREE Sample of our FcRn Binding Kit!Request a FREE Sample of our Fc gamma RI / CD64 Binding Kit !
Happy Holiday! Limited Keychain here with your next orderHappy Holiday! Limited Keychain here with your next order
Request a FREE sample of our GMP products! Request a FREE sample of our GMP products!
Cat. No. | Species | Product Description | Structure | Purity | Feature |
---|---|---|---|---|---|
TF3-C52H3 | Cynomolgus | Cynomolgus Coagulation Factor III / Tissue Factor Protein, His Tag (active enzyme, MALS verified) |
|
|
|
TF3-H5253 | Human | Human Coagulation Factor III / Tissue Factor Protein, Fc Tag (active enzyme) |
|
|
|
TF3-M52H3 | Mouse | Mouse Coagulation Factor III / Tissue Factor Protein, His Tag (MALS verified) |
|
||
TF3-H52H5 | Human | Human Coagulation Factor III / Tissue Factor Protein, His Tag (active enzyme, MALS verified) |
|
|
Anti-TF mAb immobilized on CM5 Chip can bind Human Tissue Factor, Fc Tag (Cat. No. TF3-H5253) with an affinity constant of 2.38 nM as determined in SPR assay (Biacore T200) (Routinely tested).
Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Tisotumab vedotin | TF-011-MMAE | Approved | Genmab A/S | HuMax-TF, TIVDAK | United States | Uterine Cervical Neoplasms | Seagen Inc | 2021-09-20 | Ovarian Neoplasms; Solid tumours; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Pancreatic Neoplasms; Urinary Bladder Neoplasms; Prostatic Neoplasms; Peritoneal Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
Tisotumab vedotin | TF-011-MMAE | Approved | Genmab A/S | HuMax-TF, TIVDAK | United States | Uterine Cervical Neoplasms | Seagen Inc | 2021-09-20 | Ovarian Neoplasms; Solid tumours; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Pancreatic Neoplasms; Urinary Bladder Neoplasms; Prostatic Neoplasms; Peritoneal Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Anpocogin | AB-201 | Phase 3 Clinical | Dendreon Uk Ltd | Coronavirus Disease 2019 (COVID-19) | Details |
XNW-28012 | XNW-28012; XNW28012 | Phase 2 Clinical | Shanghai Cigna Biotech Pharmaceutical Co Ltd | Solid tumours | Details |
MRG-004A | MRG004A | Phase 2 Clinical | Solid tumours | Details | |
XB-002 | XB-002; ICON-2 | Phase 1 Clinical | Iconic Therapeutics Inc | Solid tumours; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Ovarian Epithelial; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Breast Neoplasms; Urogenital Neoplasms; Esophageal Squamous Cell Carcinoma; Endometrial Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms | Details |
Anpocogin | AB-201 | Phase 3 Clinical | Dendreon Uk Ltd | Coronavirus Disease 2019 (COVID-19) | Details |
XNW-28012 | XNW-28012; XNW28012 | Phase 2 Clinical | Shanghai Cigna Biotech Pharmaceutical Co Ltd | Solid tumours | Details |
MRG-004A | MRG004A | Phase 2 Clinical | Solid tumours | Details | |
XB-002 | XB-002; ICON-2 | Phase 1 Clinical | Iconic Therapeutics Inc | Solid tumours; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Ovarian Epithelial; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Breast Neoplasms; Urogenital Neoplasms; Esophageal Squamous Cell Carcinoma; Endometrial Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms | Details |
This web search service is supported by Google Inc.